| Identification | Back Directory | [Name]
Ladarixin Sodium | [CAS]
849776-05-2 | [Synonyms]
Meraxin
Ladarixin Sodium
(R)-4-[1-(Methylsulfonamido)-1-oxo-2-propyl]phenyl Trifluoromethanesulfonate
Methanesulfonic acid, 1,1,1-trifluoro-, 4-[(1R)-1-methyl-2-[(methylsulfonyl)amino]-2-oxoethyl]phenyl ester | [Molecular Formula]
C11H12F3NO6S2 | [MDL Number]
MFCD28502169 | [MOL File]
849776-05-2.mol | [Molecular Weight]
375.34 |
| Hazard Information | Back Directory | [Uses]
Ladarixin Sodium is a a dual CXCR1/2 inhibitor. It has therapeutic potential for treating type I diabetes and various melanoma. | [in vivo]
Ladarixin (10 mg/kg; p.o. once a day) reduces allergic airway inflammation in a model of single OVA exposure. Ladarixin reduces allergic airway inflammation, remodeling, and bronchial hyperreactivity in a model of chronic OVA exposure[1].
?
Ladarixin (10 mg/kg; p.o. once a day for 8 days) reduces pulmonary inflammation and fibrosis induced by bleomycin in mice[1].
?
Ladarixin (10 mg/kg; p.o. once a day for 3 days) protects mice from cigarette smoke-induced exacerbation of influenza-A infection[1].
?
Ladarixin is also effective in decreasing CXCL8-induced polymorphonuclear leukocyte infiltration in several animal models without a significant dose-related reduction in systemic neutrophil counts[2]. | Animal Model: | Mice (cigarette smoke-induced exacerbation of Influenza-A infection model)[1] | | Dosage: | 10 mg/kg | | Administration: | P.o. once a day at days 2, 3 and 4 post-infection | | Result: | Significantly attenuated the exacerbation in lethality and respiratory changes noted in CSFlu group. |
|
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|